Recent Quotes (30 days)

You have no recent quotes
chg | %

Ovid Therapeutics Inc  

(Public, NASDAQ:OVID)   Watch this stock  
Find more results for OVID
+0.03 (0.43%)
Real-time:   11:51a.m. EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.02 - 7.27
52 week 5.28 - 15.93
Open 7.27
Vol / Avg. 12,706.00/73,126.00
Mkt cap 173.70M
P/E     -
Div/yield     -
EPS -3.87
Shares 24.60M
Beta     -
Inst. own 33%

Key stats and ratios

Q3 (Sep. '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -36.52% -36.33%
Return on average equity -38.72% -38.21%
Employees 38 -
CDP Score - -


1460 Broadway Ste 15044
NEW YORK, NY 10036-7329
United States - Map
+1-646-6617661 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

Officers and directors

Jeremy Max Levin Chairman of the Board, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Matthew During M.D. President, Chief Scientific Officer, Director
Age: 60
Bio & Compensation  - Reuters
Yaron Werber M.D. Chief Business and Financial Officer, Secretary
Age: 45
Bio & Compensation  - Reuters
Dirk Haasner Ph.D. Senior Vice President - Global Regulatory Affairs
Age: 52
Bio & Compensation  - Reuters
Timothy G. Daly Vice President - Finance, Corporate Controller
Age: 45
Bio & Compensation  - Reuters
Amit Rakhit M.D. Chief Medical and Portfolio Management Officer
Age: 47
Bio & Compensation  - Reuters
Bart Friedman Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Barbara G. Duncan Director
Age: 52
Bio & Compensation  - Reuters
Karen Bernstein Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters